H.R. 10628, Biologic Drug Pricing Delay. Quorum's AI analysis reads it as a net cost — and names who bears it.
H.R. 10628 · Net cost
What it does
This bill delays when biologic drugs become eligible for Medicare price negotiations if a cheaper biosimilar (generic-like alternative) is expected to enter the market soon. Instead of a drug entering price negotiations 9 months after FDA approval, it now stays out of negotiations for up to 2 years if a biosimilar manufacturer confirms it expects to launch within that window. If the biosimilar doesn't actually launch, the original drug enters negotiations and the biosimilar maker owes a rebate.
The analysis names reference biologic manufacturers (Amgen, Regeneron, Eli Lilly, Janssen, AbbVie, etc.) — and 1 more group — among the beneficiaries.
The cost
The bill's framing as 'biosimilar access' obscures that delaying reference drug price negotiations may reduce the price advantage of biosimilars, potentially slowing their market adoption and reducing actual biosimilar competition.
The analysis put a high warning level on this bill. Transparency scores 25%, and the analysis found no provisions unrelated to the bill's subject.
Who is behind it
Filed by Nicholas Langworthy. Cosponsored by Jake Auchincloss, Jimmy Panetta, John Joyce and Kevin Mullin.
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.